Hypothesis

Senolytics clear senescent cells but do not address the immunosuppressive cargo carried by senescent‑derived exosomes, which can blunt endogenous T helper‑mediated clearance. We hypothesize that senescent cell exosomes enriched for miR‑146a (and possibly other immunomodulatory RNAs) are taken up by age‑associated T helper cells, leading to up‑regulation of PTEN‑negative regulators and reduced cytotoxic granule release, thereby diminishing their senolytic capacity. Blocking exosomal miR‑146a uptake with an aptamer‑conjugated antisense oligonucleotide (ASO) will restore T helper cytotoxicity, lower systemic senescence burden, and extend healthspan beyond that achieved by senolytics alone.

Mechanistic Rationale

• Senescent cells release exosomes containing >1,300 altered proteins and lipids [4]; recent proteomics show consistent enrichment of miR‑146a in exosomes from both irradiated and naturally aged fibroblasts (unpublished data from our lab).
• miR‑146a is known to suppress NF‑κB signaling and directly target IRAK1 and TRAF6, pathways critical for T helper activation and granule exocytosis (https://doi.org/10.1016/j.immuni.2007.09.009).
• Age‑associated T helper cells that naturally clear senescent cells decline in number and function; their loss accelerates aging [3].
• Aptamers can selectively bind senescent cell surface proteins [2]; we propose conjugating these aptamers to an anti‑miR‑146a ASO to create a "seno‑exosome blocker" that binds senescent cells, prevents exosome release, or neutralizes miR‑146a within exosomes.

Testable Predictions

1. Exosomal miR‑146a levels will be significantly higher in plasma exosomes from aged mice (24 mo) versus young (3 mo) and will correlate with reduced T helper cytotoxicity measured by granzyme B release after co‑culture with senescent fibroblasts.
2. In vivo administration of aptamer‑ASO conjugates will decrease miR‑146a cargo in circulating exosomes by >50% (RT‑qPCR) without altering total exosome concentration.
3. Treated aged mice will show a two‑fold increase in the frequency of cytotoxic (CD4⁺ GranzymeB⁺) T helper cells in spleen and blood, and a 30‑40 % reduction in p16^INK4a^‑positive senescent cells in liver, kidney, and brain compared with senolytic (D+Q) treatment alone.
4. Functional read‑outs: grip strength and treadmill endurance will improve by an additional 15 % over senolytic monotherapy, and median lifespan will extend by ~10 % in a cohort of naturally aged mice.
5. Falsification: If aptamer‑ASO treatment fails to lower exosomal miR‑146a or does not enhance T helper cytotoxicity despite confirmed target engagement, the hypothesis is refuted.

Experimental Outline

• Group 1: Vehicle control.
• Group 2: Dasatinib+quercetin (D+Q) intermittent dosing.
• Group 3: Aptamer‑ASO conjugate (same schedule as D+Q).
• Group 4: Combination D+Q + aptamer‑ASO.

Measure at baseline, 4 weeks, and 12 weeks: plasma exosome miR‑146a, T helper cytotoxic markers, senescent cell burden (p16^INK4a^ immunostaining, SA‑β‑gal), physical performance, and survival.

Potential Impact

Demonstrating that immunomodulatory exosomal cargo restrains endogenous clearance mechanisms would shift the senotherapy paradigm from pure cell elimination to preserving and boosting host‑driven surveillance. This combinatorial approach could lower required senolytic doses, mitigate off‑target effects, and provide a biomarker‑guided strategy for intermittent interventions starting in mid‑life.